Get the Stockscreener App
14.56
1.96%
0.28
After Hours:
14.59
0.03
+0.21%
Rallybio Corp stock is traded at $14.56, with a volume of 237.62K.
It is up +1.96% in the last 24 hours and up +79.31% over the past month.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
See More
Previous Close:
$14.28
Open:
$14.05
24h Volume:
237.62K
Relative Volume:
0.76
Market Cap:
$77.02M
Revenue:
$858.00K
Net Income/Loss:
$-8.98M
P/E Ratio:
-70.71
EPS:
-0.2059
Net Cash Flow:
$-29.81M
1W Performance:
+63.96%
1M Performance:
+79.31%
6M Performance:
+184.91%
1Y Performance:
+512.38%
1-Day Range:
$13.86
$14.59
1-Week Range:
$8.70
$15.31
52-Week Range:
$2.16
$15.31
Rallybio Corp Stock (RLYB) Company Profile
Name
Rallybio Corp
Sector
Industry
Phone
203- 859-3820
Address
234 CHURCH STREET, NEW HAVEN
Compare RLYB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
14.56 | 75.54M | 858.00K | -8.98M | -29.81M | -0.2059 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-07-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-17-23 | Initiated | H.C. Wainwright | Buy |
| Apr-10-23 | Initiated | Wedbush | Outperform |
| Dec-09-22 | Initiated | JP Morgan | Overweight |
| Feb-22-22 | Initiated | JMP Securities | Mkt Outperform |
| Aug-23-21 | Initiated | Cowen | Outperform |
| Aug-23-21 | Initiated | Evercore ISI | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
View All
Rallybio Corp Stock (RLYB) Latest News
[RW] Rallybio Corp SEC Filing - Stock Titan
Rallybio stock surges after receiving $50M termination fee By Investing.com - Investing.com Nigeria
Rallybio stock surges after receiving $50M termination fee - Investing.com
Rallybio merger scrapped; New Haven biotech to receive $50M breakup fee - Hartford Business Journal
Rallybio Corporation Files Form 8-K with SEC Detailing Waiver Agreement and Entity Information - Minichart
RLYB Stock Under Pressure As Merger Scrutiny Mounts - timothysykes.com
Rallybio Receives Termination Fee After Candid Deal Collapse - TipRanks
Rallybio, Candid and UCB Sign Waiver; $50 Million Fee Follows Merger Termination - TradingView
Rallybio CorpCandid terminates merger agreement with Rallybio on May 3, 2026SEC filing - marketscreener.com
Rallybio (RLYB) to receive $50,000,000 after Candid chooses UCB deal - Stock Titan
RLYB - Finviz
RLYB Stock Chart | RALLYBIO CORP (NASDAQ:RLYB) - ChartMill
[S-4/A] Rallybio Corp Amended Business Combination Registration | RLYB SEC FilingForm S-4/A - Stock Titan
Rallybio Corporation (RLYB) Sector Rotation | Rallybio Corporation notches 13.9% EPS beat on narrower lossCommunity Buy Signals - Xã Vĩnh Công
Is Rallybio Corporation (RLYB) stock a good opportunity (Institutional Demand) 2026-04-20Social Flow Trades - Cổng thông tin điện tử Tỉnh Sơn La
Johnson & Johnson Reduces Stake in Rallybio Corp: A Strategic Po - GuruFocus
Rallybio Corporation (RLYB) Stock: Price Structure (Hovering) 2026-04-16Trending Stock Ideas - Cổng thông tin điện tử Tỉnh Sơn La
Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders? - Eastern Progress
J&J (NYSE: JNJ) discloses 152,901‑share stake in Rallybio (RLYB) - Stock Titan
Will Rallybio Corporation (RLYB) Stock Outperform S&P 500 | Price at $8.24, Down 2.31%Top Breakouts - UBND thành phố Hải Phòng
RLYB Stock Quote - richtv.io
Rallybio Investors Confront Significant Dilution in Merger as $47.5M Valuation Marks Major Downturn from Earlier Projections - Bitget
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Terns Therapeutics, Inc. (Nasdaq – TERN), Whitestone REIT (NYSE – WSR), Rallybio Corporation (Nasdaq – RLYB), Day One Biopharmaceuticals, Inc. (Nasda - ChartMill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Are EWCZ, STEL, RLYB, CTRA Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
Setup Watch: Can Rallybio Corporation sustain earnings growth2026 Movers & Precise Entry and Exit Recommendations - baoquankhu1.vn
Is Rallybio Corporation (RLYB) Stock cyclical or stable | Price at $8.43, Up 0.36%Short Term Trading - Xã Thanh Hà
RLYB Technical Analysis & Stock Price Forecast - Intellectia AI
Rallybio CMO Departs Amid Pending Candid Therapeutics Merger - The Globe and Mail
AI Stocks: Is Rallybio Corporation stock trending bullishWeekly Trade Report & Daily Price Action Insights - baoquankhu1.vn
Rallybio chief medical officer departs as company announces leadership change By Investing.com - Investing.com South Africa
Rallybio chief medical officer departs as company announces leadership change - Investing.com Australia
Rallybio (RLYB) CMO Steven Ryder exits as Candid Therapeutics merger proceeds - Stock Titan
RLYB Should I Buy - Intellectia AI
RALLYBIO CORP (NASDAQ:RLYB) Passes Minervini Trend and High Growth Momentum Filters - ChartMill
Rallybio (NASDAQ:RLYB) Rating Increased to Hold at Wall Street Zen - Defense World
Rallybio to acquire Candid Therapeutics - MSN
Rallybio to acquire Candid Therapeutics in $505M merger deal - MSN
If You Invested $1,000 in Rallybio Corp (RLYB) - Stock Titan
Here's Why We're Watching Rallybio's (NASDAQ:RLYB) Cash Burn Situation - 富途牛牛
Halper Sadeh LLC is Investigating Whether RLYB, TALK, UNF are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Tiny biotech Rallybio stock surges as $500 million-backed merger fuels investor optimism - msn.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations - marketscreener.com
Rallybio CVRs Carry High Risk of Expiring Worthless Amid Uncertain Asset Monetization - TipRanks
Halper Sadeh LLC is Investigating Whether TALK, JTAI, RLYB are Obtaining Fair Deals for their Shareholders - The Norfolk Daily News
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—ALIS, TALK, JTAI, and RLYB - GlobeNewswire Inc.
Rallybio Corporation 2025 10-K: Clinical-Stage Rare Disease Biotech, Pipeline, Partnerships, and Regulatory Overview - Minichart
RLYB Surges on Revenue and Merger Hype Why the Stock Still Dropped - Bitget
Stock Recap: What hedge funds are buying Rallybio CorporationPortfolio Value Summary & Weekly High Conviction Ideas - baoquankhu1.vn
Rallybio (NASDAQ: RLYB) to become Candid after merger, $505.5M financing - Stock Titan
Rallybio 2025 10-K: $0.858M Revenue, $(8.98)M Net Loss - TradingView
Rallybio Corp Stock (RLYB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):